Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.
Meneyrol J, Follmann M, Lassalle G, Wehner V, Barre G, Rousseaux T, Altenburger JM, Petit F, Bocskei Z, Schreuder H, Alet N, Herault JP, Millet L, Dol F, Florian P, Schaeffer P, Sadoun F, Klieber S, Briot C, Bono F, Herbert JM. Meneyrol J, et al. Among authors: briot c. J Med Chem. 2013 Dec 12;56(23):9441-56. doi: 10.1021/jm4005835. Epub 2013 Dec 3. J Med Chem. 2013. PMID: 24175584
N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist.
Boldron C, Besse A, Bordes MF, Tissandié S, Yvon X, Gau B, Badorc A, Rousseaux T, Barré G, Meneyrol J, Zech G, Nazare M, Fossey V, Pflieger AM, Bonnet-Lignon S, Millet L, Briot C, Dol F, Hérault JP, Savi P, Lassalle G, Delesque N, Herbert JM, Bono F. Boldron C, et al. Among authors: briot c. J Med Chem. 2014 Sep 11;57(17):7293-316. doi: 10.1021/jm500588w. Epub 2014 Aug 25. J Med Chem. 2014. PMID: 25075638
Disposition of tiludronate (Skelid) in animals.
Davi H, Tronquet C, Caix J, Simiand J, Briot C, Berger Y, Thiercelin JF. Davi H, et al. Among authors: briot c. Xenobiotica. 1999 Oct;29(10):1017-31. doi: 10.1080/004982599238083. Xenobiotica. 1999. PMID: 10574683
Hepatic Artery Aneurysm Causing Biliary Compression.
El Ouardi W, El Mansoury FZ, Claude G, Briot C, Faivre M. El Ouardi W, et al. Among authors: briot c. ACG Case Rep J. 2024 Mar 22;11(3):e01300. doi: 10.14309/crj.0000000000001300. eCollection 2024 Mar. ACG Case Rep J. 2024. PMID: 38524257 Free PMC article.
Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients.
Chapuis-Biron C, Bourrier A, Nachury M, Nancey S, Bouhnik Y, Serrero M, Armengol-Debeir L, Buisson A, Tran-Minh ML, Zallot C, Fumery M, Bouguen G, Abitbol V, Viennot S, Chanteloup E, Rajca S, Dib N, Parmentier AL, Peyrin-Biroulet L, Vuitton L; GETAID BioLAP Study Group. Chapuis-Biron C, et al. Aliment Pharmacol Ther. 2020 Apr;51(7):719-727. doi: 10.1111/apt.15665. Epub 2020 Feb 20. Aliment Pharmacol Ther. 2020. PMID: 32080886
Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study.
Briot C, Faure P, Parmentier AL, Nachury M, Trang C, Viennot S, Altwegg R, Bulois P, Thomassin L, Serrero M, Ah-Soune P, Gilletta C, Plastaras L, Simon M, Dray X, Caillo L, Del Tedesco E, Abitbol V, Zallot C, Degand T, Rossi V, Bonnaud G, Colin D, Morel B, Winkfield B, Danset JB, Filippi J, Amiot A, Attar A, Levy J, Peyrin-Biroulet L, Vuitton L; CLEAN Study Group. Briot C, et al. J Crohns Colitis. 2019 Sep 19;13(9):1121-1130. doi: 10.1093/ecco-jcc/jjz040. J Crohns Colitis. 2019. PMID: 30785181
26 results